349 completed, 126 terminated, 102 recruiting, 89 unknown. 762 Phase 2, 210 Phase 1, 13 Phase 3.
Follow Ovarian Cancer: new trials by email Literature Review of Ovarian Cancer trials Research Report on Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. TJ102 - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Phrontline Biopharma | 150 | 2026-09-29 | 2026-10-21 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer SYS6041, bevacizumab, SYS6041, carboplatin, bevacizumab, paclitaxel, carboplatin, bevacizumab - Ovarian Cancer, Recurrent Ovarian Cancer | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 171 | 2026-08-13 | 2026-08-31 |
| Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) avutometinib + defactininb combination - Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Not yet recruiting | Verastem, Inc. | 2 | 2026-08-03 | 2026-08-05 |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer Ubamatamab, Chemotherapy, Bevacizumab - Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 43 | 2026-08-01 | 2026-07-10 |
| Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer Olaparib+Bevacizumab, Fluzoparib+Bevacizumab - Ovarian Cancer | Phase 2 | Not yet recruiting | Shandong University | 120 | 2026-06-30 | 2026-06-15 |
| Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II） Neoadjuvant Therapy Plus Surgery - Ovarian Cancer | Phase 2 | Not yet recruiting | Obstetrics & Gynecology Hospital of Fudan University | 49 | 2026-06-06 | 2026-06-29 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations INV-8989 - Advance Solid Tumors, Colon and Rectal Cancer | Phase 1 / Phase 2 | Recruiting | Shenzhen Ionova Life Sciences Co., Ltd. | 178 | 2026-06-01 | 2026-06-10 |
| Engineered Immune Effectors Against Ovarian Cancer OC-CTLs - Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2026-06-01 | 2026-11-03 |
| Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT N-Acetyl-Cysteine, Placebo - Ovarian Cancer, Cognitive Impairment | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 102 | 2026-05-21 | 2026-07-17 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
Showing 20 of 762. Sign in to see all of them.
Ovarian Neoplasms (762) · Fallopian Tube Neoplasms (191) · Carcinoma, Ovarian Epithelial (168) · Breast Neoplasms (92) · Endometrial Neoplasms (72) · Neoplasms (61) · Carcinoma, Non-Small-Cell Lung (56) · Colorectal Neoplasms (55) · Sarcoma (53) · Pancreatic Neoplasms (47) · Recurrence (47) · Uterine Cervical Neoplasms (47) · Stomach Neoplasms (42) · Lung Neoplasms (34) · Neoplasm Metastasis (34)
Endocrine Gland Neoplasms (762) · Female Urogenital Diseases (762) · Female Urogenital Diseases and Pregnancy Complications (762) · Genital Diseases (762) · Gonadal Disorders (762) · Urogenital Diseases (762) · Adnexal Diseases (761) · Endocrine System Diseases (761) · Genital Diseases, Female (760) · Neoplasms by Site (759) · Genital Neoplasms, Female (758) · Ovarian Diseases (756) · Urogenital Neoplasms (756) · Neoplasms (701) · Neoplasms by Histologic Type (291)
Carboplatin (128) · Paclitaxel (117) · Bevacizumab (66) · Gemcitabine (43) · Cyclophosphamide (35) · pembrolizumab (35) · Cisplatin (29) · Topotecan (29) · liposomal doxorubicin (28) · Filgrastim (26) · Docetaxel (23) · olaparib (23) · Etoposide (19) · niraparib (19) · Peripheral Blood Stem Cell Transplantation (16)
Memorial Sloan Kettering Cancer Center (30) · Gynecologic Oncology Group (23) · National Cancer Institute (NCI) (19) · M.D. Anderson Cancer Center (16) · Dana-Farber Cancer Institute (14) · Eli Lilly and Company (13) · ARCAGY/ GINECO GROUP (10) · Masonic Cancer Center, University of Minnesota (10) · AstraZeneca (9) · NYU Langone Health (8) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Fred Hutchinson Cancer Center (7) · North Eastern German Society of Gynaecological Oncology (7) · Sun Yat-sen University (7) · Genentech, Inc. (6)
United States (432) · China (87) · United Kingdom (80) · Canada (73) · Spain (60) · France (54) · Italy (46) · Belgium (42) · Australia (41) · Germany (40) · South Korea (29) · Denmark (22) · Netherlands (22) · Poland (18) · Israel (17)
Paul Sabbatini, MD (5) · Amy D. Tiersten, MD (4) · Franco Muggia, MD (4) · Robert J. Motzer, MD (4) · Steven A Rosenberg, M.D. (4) · Ursula Matulonis, MD (4) · Alexander B Olawaiye, MD (3) · Amir Jazaeri, MD (3) · Amit Oza, M.D. (3) · Angeles A Secord, MD (3)
PMID 37185961, PMID 35170751, PMID 35537408, PMID 19238149, PMID 28935273, PMID 31685558, PMID 35397664, PMID 36718018, PMID 37407274, PMID 39123210, PMID 11705489, PMID 11919245, PMID 12065559, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12826431, PMID 12957454, PMID 14534883, PMID 14615449, PMID 14645425, PMID 14701774, PMID 14767498, PMID 14970858, PMID 15010069, PMID 15177491, PMID 15581974, PMID 15589582, PMID 15592836, PMID 15659504, PMID 15661234, PMID 15699482, PMID 15721430, PMID 15864277, PMID 15999362, PMID 16014111, PMID 16061871, PMID 16249022, PMID 16314647, PMID 16325893, PMID 16500907, PMID 16643994, PMID 17018256, PMID 17105988, PMID 17126894, PMID 17161453, PMID 17194908, PMID 17290059, PMID 17330838
P30CA008748 (7), 2008 (6), 2009 (6), 2016 (6), 2017 (4), 2023 (4), 2025 (4), U10CA032102 (4), 2018 (3), 2015 (2), P30CA016087 (2), P30CA033572 (2), P01CA132714 (1), P30CA006516 (1), P30CA013330 (1)